{
    "id": 11029,
    "fullName": "NFE2L2 D29H",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "NFE2L2 D29H lies within a hotspot mutation region in the DLG motif in the NEH2 Keap1 binding domain of the Nfe2l2 protein (PMID: 19321346, PMID: 24366543). D29H confers a gain of function to the Nfe2l2 protein as demonstrated by loss of Keap1 repressor binding (PMID: 24366543) and is transforming in cell culture (PMID: 28145866).",
            "references": [
                {
                    "id": 3571,
                    "pubMedId": 19321346,
                    "title": "NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19321346"
                },
                {
                    "id": 3572,
                    "pubMedId": 24366543,
                    "title": "Kinetic, thermodynamic, and structural characterizations of the association between Nrf2-DLGex degron and Keap1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24366543"
                },
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4780,
        "geneSymbol": "NFE2L2",
        "terms": [
            "NFE2L2",
            "HEBP1",
            "IMDDHH",
            "Nrf-2",
            "NRF2"
        ]
    },
    "variant": "D29H",
    "createDate": "08/28/2015",
    "updateDate": "06/03/2019",
    "referenceTranscriptCoordinates": {
        "id": 133777,
        "transcript": "NM_006164",
        "gDna": "chr2:g.177234232C>G",
        "cDna": "c.85G>C",
        "protein": "p.D29H",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17252,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Sapanisertib (MLN0128) treatment of a squamous cell lung cancer patient, harboring NFE2L2 D29H, resulted in a duration of response of 8 months and was ongoing (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 9098-9098).",
            "molecularProfile": {
                "id": 11072,
                "profileName": "NFE2L2 D29H"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15272,
                    "pubMedId": null,
                    "title": "Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11921,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of NFE2L2 (NRF2) D29H resulted in decreased sensitivity to Tarceva (erlotinib) in a lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 28145866).",
            "molecularProfile": {
                "id": 28352,
                "profileName": "EGFR E746_A750del NFE2L2 D29H NFE2L2 over exp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9896,
                    "pubMedId": 28145866,
                    "title": "KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28145866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11072,
            "profileName": "NFE2L2 D29H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28352,
            "profileName": "EGFR E746_A750del NFE2L2 D29H NFE2L2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 133776,
            "transcript": "NM_001313902",
            "gDna": "chr2:g.177234232C>G",
            "cDna": "c.85G>C",
            "protein": "p.D29H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 133775,
            "transcript": "NM_001313903",
            "gDna": "chr2:g.177234232C>G",
            "cDna": "c.85G>C",
            "protein": "p.D29H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 133777,
            "transcript": "NM_006164",
            "gDna": "chr2:g.177234232C>G",
            "cDna": "c.85G>C",
            "protein": "p.D29H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}